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CRITICAL REVIEW
A portfolio of biologic self-injection devices in rheumatology: how patient
involvement in device design can improve treatment experience
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ABSTRACT
Biologic drugs (e.g. anti-tumor necrosis factors) are effective treatments for multiple chronic inflamma-
tory diseases including rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis.
Administration of biologic drugs is usually via subcutaneous self-injection, which provides many
patient benefits compared to infusions including increased flexibility, reduced costs, and reduced care-
giver burden. However, it is also associated with challenges such as needle phobia, patient treatment
misconceptions and incorrect drug administration, and can be impacted by dexterity problems.
Evidence suggests these problems, along with other drug administration challenges (e.g. patient for-
getfulness, busy lifestyles, and polypharmacy), can reduce patient adherence to treatment. To combat
these challenges, patient feedback has been used to develop a range of self-injection devices, includ-
ing pre-filled syringes, pre-filled pens, and electronic injection devices. Providing different devices for
drug administration gives patients the opportunity to choose a device that addresses the challenges
they face as an individual. Research suggests involving patients in medical device development, pro-
viding patients with a choice of devices and enrolling individuals in patient support programs can
empower patients to take control of their treatment journey. By providing a portfolio of self-injection
devices, designed based on patient needs, patient experience will improve, potentially improving
adherence and hence, long-term treatment outcomes.
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1. Introduction
Anti-tumor necrosis factor (anti-TNF) biologic drugs have
emerged as effective and safe at treating a range of chronic
inflammatory diseases, including axial spondyloarthritis
(axSpA), Crohn’s disease (CD), psoriasis (PSO), psoriatic arth-
ritis (PsA) and rheumatoid arthritis (RA) (Sivamani et al., 2013;
Maruotti & Cantatore, 2014; Wang et al., 2014; Mease, 2015;
Trivedi & Hanauer, 2015). The use of biological disease-modi-
fying antirheumatic drugs (bDMARDs), often alongside con-
ventional disease-modifying antirheumatic drugs (cDMARDs),
such as methotrexate, has resulted in better long-term dis-
ease control and reduced functional impairment.
Anti-TNF biologic drugs are protein molecules and so are
easily broken down by the digestive system; therefore
administration is usually via injection (Schiff et al., 2017). To
reduce the impact of treatment administration on patients’
lives, self-injection devices, able to inject anti-TNFs subcuta-
neously, have been developed. Once trained, patients can
self-administer their prescribed biologic agent without add-
itional help (Lyseng-Williamson, 2017). By removing the
need of a healthcare professional (HCP) or caregiver, patient
self-injection is associated with a wide range of benefits
compared to infusion therapy, including increased flexibility
in the time and place of injection administration, reduced
cost to both the patient and healthcare system, reduced
travel time, and reduced caregiver burden (Cross et al., 2006;
Keininger & Coteur, 2011). Overall, this leads to increased
patient control, self-efficacy, and autonomy, reducing the
psychological burden of disease and improving quality of life
(Salmon & Hall, 2003). Self-injection is also associated with a
number of challenges. These include needle phobia, fear and
anxiety, concerns about pain, stinging, and other injection
site reactions, patient lack of confidence, incorrect adminis-
tration, medication non-adherence, and the struggle to use a
self-injection device while suffering from arthritic pain and
swelling of the hands (Schwartzman & Morgan, 2004;
Keininger & Coteur, 2011; Schiff et al., 2017). Self-injection
device design can help overcome some of the challenges
associated with self-injection, improving ease of use, and
ultimately aiding disease management and improving long-
term outcomes (Maniadakis et al., 2018).
The aims of this narrative review article are to describe
current self-injection devices and the device development
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process including how patients can influence development,
based on a pragmatic review of the literature. In addition,
this article explores how using a portfolio of different self-
injection devices may help address the needs of patient pop-
ulations in different disease areas.
2. Device options
Three main types of device have been developed for the
administration of biologic agents in chronic inflammatory
diseases: pre-filled syringes (PFS), pre-filled pens (PFP), and
electronic injection devices (e-Devices). These different devi-
ces have been developed in response to the challenges and
preferences of patients using self-injection devices with the
aim of improving patient experience during self-injection
(Sheikhzadeh et al., 2012; Lange et al., 2014; Schulze-Koops
et al., 2015; Schiff et al., 2016; Lyseng-Williamson, 2017).
A PFS is an injection system consisting of a needle and
syringe (Sheikhzadeh et al., 2012); the syringe is pre-filled
with the appropriate drug dose reducing the time taken to
inject, decreasing the chance of microbiological contamin-
ation and reducing the likelihood of dosing errors (Table 1)
(Makwana et al., 2011). The physical features of the syringe
(e.g. finger flange, plunger rod, and needle cap) can be
designed to help with self-injection, for example, the flanges
can be increased in size to help rheumatic patients handle
the device (Sheikhzadeh et al., 2012).
The PFP is a self-injection pen designed to automate the
injection process (Table 2) (Kivitz et al., 2006; Kivitz &
Segurado, 2007; Lange et al., 2014; Domanska et al., 2017).
Table 1. Available PFS for anti-TNF administration and their associated features.
Brand name Key features and benefits
ENBRELVR (Etanercept) Muller-Ladner et al., 2012  PFS, no mixing required
 Finger flange
 Manually injected so patients can control the speed of injection
HUMIRAVR (Adalimumab) Kivitz et al., 2006  PFS, no mixing required
 Finger flange
 Manually injected so patients can control the speed of injection
SIMPONIVR (Golimumab) Vermeire et al., 2018  PFS, no mixing required
 Manually injected so patients can control the speed of injection
 Needle retracts following the injection
CIMZIAVR (Certolizumab pegol) Sheikhzadeh et al., 2012  PFS, no mixing required
 Large thumb pad and plunger rod
 Non-slip, robust finger grip/flange, greater force can be applied
 Oval syringe barrel
 Round finger loop on the needle cap
BenepaliVR (Etanercept) EMA, 2018  PFS, no mixing required
 Finger flange
PFS: pre-filled syringe; TNF: tumor necrosis factor.
Table 2. Available PFP for anti-TNF administration and their associated features.
Brand name Key features and benefits
ENBRELVR (Etanercept) Muller-Ladner
et al., 2012
 Needle not visible to patients
 Safety needle cover unlocks when the PFP is
in place
 One button click
 Audible clicks to confirm injection completion
 Large inspection window
 Easy to use, less handling and patient confident
dose is administered
HUMIRAVR (Adalimumab) Kivitz and
Segurado, 2007
 Needle not visible to patients
 One touch activation
 Easy to grip
 Audible click to signal the start of injection
 Viewing window
 Improved ease of use for RA patients
 Patient confident dose is administered
 Less painful for some patients
SIMPONIV
R
(Golimumab) Vermeire
et al., 2018
 Needle not visible to patients
 Ergonomically shaped pen
 Safety needle cover – unlocks when device is
placed firmly against the injection site
 One button click
 Audible clicks to signal injection start
and completion
 Viewing window
 Improved ease of use for RA patients
 Patient confident dose is administered
 Mechanisms to prevent accidental/prema-
ture injection
CIMZIAVR (Certolizumab pegol)
Domanska et al., 2017b
 Needle not visible to patients
 Button-free injection
 Anti-roll shape device
 Wide, non-slip, latex-free grip
 A large gripping area on the cap
 Audible clicks to signal injection start
and completion
 Display window
 Orange band to indicate when device is ready
to use, closes upon injection initiation
 Patient confident dose is administered
 Designed with input from RA patients to
improve comfort and ease of use dur-
ing injection
BenepaliVR (Etanercept) EMA, 2018  Needle not visible to patients
 Audible click to signal start of injection
 Viewing window
PFP: pre-filled pen; RA: rheumatoid arthritis; TNF: tumor necrosis factor.
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Automated activation (e.g. by push button), audible clicks, a
hidden needle and a viewing window for observing injection
progress all aim to improve ergonomics, make the injection
process easier, and increase patient confidence (Freundlich
et al., 2014; Lange et al., 2015; Domanska et al., 2017b).
Most recently e-Devices have been developed based on
the PFP design but offering more enhanced technical fea-
tures (Table 3). They are reusable and electronic with
advanced technical functions to support disease manage-
ment such as on-screen instructions, injection log, skin sen-
sor, and injection speed control. Furthermore, the e-Device
can include features to maximize injection safety; for
example, an automatic injection stop when skin contact is
lost, the same automatic needle insertion and retraction as
seen in PFPs, and a medication information chip reader to
ensure medication authenticity and use-by-date (Domanska
et al., 2018). As e-Devices are reusable with disposable medi-
cine cartridges, practice ‘cartridges’ that do not contain
medicine have been developed to allow patients to gain
confidence using the e-Device (Domanska et al., 2018).
3. Development of devices
Development of self-injection devices is increasingly focused
on patient needs, with patient feedback being incorporated
at many stages of device design (Figure 1) (Schiff et al.,
2016; Schulze-Koops et al., 2015; Domanska et al., 2018).
During the early stages of device design, focus groups are
often used to collect information about the unmet needs of
the intended users (e.g. patients, caregivers, HCPs) of the
fully developed medical device. Feedback from these groups
is then used to develop early prototype devices (Keininger &
Coteur, 2011; Schiff et al., 2016; Schiff et al., 2017).
Following the design and development of the prototype
device, formative human factors studies (HFS) are used to
assess and iteratively improve the prototype design, the
Table 3. Available e-Devices for anti-TNF administration and their associated features.
Brand name Key features and benefits
ENBRELV
R
(Etanercept) Collier et al., 2017  Reusable electronic injection device
 Designed with patients in mind with a comfortable gray finger grip
 Easy-to-press status button to start injection
 Progress bar to help track the injection process from start to finish
 Audible sounds to help track the injection
 Needle not visible to patients
 Automated self-injection
 Automatic needle insertion, dose administration and needle retraction
 Control speed of injection
CIMZIAVR (Certolizumab pegol) Domanska et al., 2018  First reusable electronic injection device in rheumatology
 Training dose dispenser
 Automated self-injection
 Automatic needle insertion, dose administration and needle retraction
 Needle not visible to patients
 Step-by-step guidance
 Interactive GUI
 Injection log and on-screen injection notifications
 Skin sensor and emergency stop when skin contact is lost to minimize drug loss
 Medication information chip for security (authenticity and use-by-date)
 Control speed of injection
GUI: Graphical User Interface; TNF: tumor necrosis factor.
Figure 1. The self-injection device development process.
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packaging and the readability of the instructions for use
(Lange et al., 2014; Lange et al., 2015; Schiff et al., 2016;
Domanska et al., 2018). Participants can include healthy vol-
unteers, patients, caregivers, and HCPs who are asked to
simulate using the device (e.g. inject an artificial skin pad)
and answer questions on device usability. User feedback is
then incorporated into the next iteration of the device
design before conducting another formative HFS to assess
the updated version. Formative HFS aim to guide the devel-
opment process and ensure the device is effectively address-
ing all identified patient needs (Domanska et al., 2018). This
process helps to guarantee device safety and that patients
use the device as intended. This includes identifying any
usability problems or use-errors and ensuring any modifica-
tions to the prototype design are effective (FDA, 2016b).
3.1. Key regulatory steps required for approval
For medical devices to be granted approval in the US or EU,
the Food and Drug Administration (FDA) and European
Medicines Agency (EMA) require evidence that the device is
safe and effective for use by the intended users, for the
intended uses, and for the intended use environments. The
FDA and EMA both require this evidence to be in the form
of a validation HFS (Panescu, 2009; French-Mowat & Burnett,
2012; FDA 2016a; MHRA 2017).
Validation HFS are conducted on the finalized device, rep-
resentative of the launch product, with the aim to validate
the safety and effectiveness of both the device and instruc-
tions for use. Participants are not trained but are provided
with the instructions for use for guidance and are monitored
while using the device to perform a simulated self-injection.
Users are assessed against a number of pre-defined tasks
that have been identified as critical for the patient to use the
device safely and effectively; these are termed critical tasks
(FDA, 2016b). Participants are individuals expected to use
the device in a real-world setting. Results of validation HFS
are used as part of the submission to the FDA/EMA for
device approval. In some cases, clinical studies are also
required alongside a validation HFS, for example, bioequiva-
lence studies comparing devices and clinical studies to dem-
onstrate safe and effective use (FDA, 2016b).
3.2. Patient empowerment and the implementation of
new device technology
Sub-optimal adherence is a challenge associated with all
DMARDS including biologic therapies (Fidder et al., 2013;
Lopez-Gonzalez et al., 2015; Maniadakis et al., 2018), and has
implications for both clinical and patient-reported outcomes,
and treatment costs. For example, non-adherence has consist-
ently been associated with increased morbidity and mortality,
and reduced treatment benefit and symptomatic improve-
ment (Bluett et al., 2015; Pasma et al., 2015; Maniadakis et al.,
2018). Device development is increasingly focusing on patient
preference and satisfaction as evidence suggests improved
patient experience with drug administration can have a posi-
tive effect on adherence to therapy (Schwartzman & Morgan,
2004; Sheikhzadeh et al., 2012).
Patient preference studies, which compare new devices
with already-approved self-injection devices, can provide
insights into the impact of modifying device features on
patient preference and give an indication of whether these
features will help improve treatment experience. In prefer-
ence studies, patients compare and rate different injection
devices based on their individual preferences and satisfaction
resulting in a scientific and clinical assessment of patient
opinions. Preference studies can provide evidence that a spe-
cific device is preferred over competitors, and provide an
opportunity for patients to give feedback on why they prefer
certain devices over others (Lyseng-Williamson, 2017). Patient
preference studies can also be feature-specific, asking
patients to rank individual features of a medical device to
determine the features patients consider most important or
useful (Domanska et al., 2017a). Additionally, a preference
study may be an HFS if comparing a device against a com-
petitor device, or a clinical study if preference between dif-
ferent devices for the same drug is investigated.
Discrete choice experiments (DCE) are another method of
investigating user preference of different devices and design
features. DCE studies are a quantitative technique to investi-
gate the role each attribute plays in determining patients’
preference for a device or feature (Harrison et al., 2015). Users
answer multiple questions stating their preference between
two or more hypothetical devices. Each hypothetical device is
defined by several varying attributes and responses are used
to determine patient preference for each attribute and each
attribute’s relative importance (Mangham et al., 2009).
Through DCE and preference studies, patients are given the
opportunity to feedback what devices and features they prefer
and prioritize (Fraenkel et al., 2004; Kivitz et al., 2006; Finckh
et al., 2016; Collier et al., 2017). This ability to influence the
development of devices empowers patients, giving them a
way to guide how treatment is administered.
A more recently developed method to elicit patient feed-
back is the Parker Model (Jrgensen et al., 2018). The Parker
Model is a composite, three-step, qualitative research model
designed to evaluate the development and implementation
of new medical devices. The model combines concept map-
ping of patient views about the e-Device with iterative par-
ticipatory design sessions to develop e-Device prototypes
that capture the feedback of all patients. Finally, patient and
disease management stakeholders are involved in group and
individual stakeholder evaluations of the e-Device
(Jrgensen et al., 2018). Each step of the model aims to sup-
port the flow of information between participants and high-
light key themes in users’ responses to new medical devices.
This process of evaluation can help identify insights that can
feed back into new iterations of medical devices and can
help ensure new device technologies are introduced to new
users in the most effective way.
4. Factors impacting patient adherence that can be
addressed using optimized device design
Multiple factors, both general and specific to chronic inflam-
matory diseases, influence treatment adherence and
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successful self-injection. Generally, reasons for treatment
non-adherence can be grouped into two categories: con-
scious and unconscious non-adherence.
Conscious non-adherers actively avoid administering
medication for reasons such as concerns about treatment
efficacy or side effects, or beliefs about medication or health-
care generally (Michetti et al., 2017). Evidence suggests
reducing medication concerns and increasing family and HCP
support may help reduce this form of non-adherence (van
den Bemt & van Lankveld, 2007; Gadallah et al., 2015;
Morgan et al., 2015). It has been suggested that a wider rec-
ognition of the role of conscious psychological factors,
including medication beliefs, could help improve treatment
adherence and improve clinical and economic outcomes
(Morgan et al., 2015).
Unconscious non-adherence is a form of non-intentional
non-adherence often driven by patients’ inability to take
their medication. This could include forgetfulness, misunder-
standing of the drug regimen, a lack of patient motivation,
needle phobia, and problems with hand dexterity and drug
administration when using non-ergonomically adapted
syringes. Many of the factors driving unconscious non-adher-
ence, such as those above, can be addressed by improving
the design of a self-injection device.
Evidence suggests forgetfulness (erratic non-adherence)
may account for 50% of non-adherence, despite patients
expressing a strong willingness to try new medicines and
adhere to effective treatment (Feldman, 2013). Polypharmacy
may exacerbate this, with evidence suggesting that taking
more than three types of medication daily or increasing the
dosing frequency is likely to increase rates of non-adherence
(Saini et al., 2009; Bugni et al., 2012). Limited health literacy
and low educational level have also been associated with
non-adherence. It has been suggested patient education pro-
grams to increase patient understanding of the disease area
and potential treatment benefits may improve levels of this
type of unconscious non-adherence (Horne et al., 2013;
Pasma et al., 2013; Joplin et al., 2015). Applying patient edu-
cation to self-injection has had some success at improving
rates of adherence. For example, an education session about
switching from a PFS to a PFP was found to increase adher-
ence following the switch to the PFP in a group of patients
prescribed etanercept (Borras-Blasco et al., 2013). However,
there are few studies in this area and so more research
focusing on the impact of specific educational strategies is
needed (Galo et al., 2016).
Reduced psychological well-being can also be a reason
for unconscious non-adherence. Unmanaged persistent anx-
iety and depression are associated with poorer health out-
comes over time, including raised tender joint count, Disease
Activity Score (DAS28) and Health Assessment Questionnaire
(HAQ) score in RA (Hider et al., 2009; Matcham et al., 2016;
Maniadakis et al., 2018). Low mood coupled with misconcep-
tions and a poor understanding of their chronic conditions
may lead to dissatisfaction with clinical consultation and
inappropriate avoidance of treatment, non-adherence and
poor disease management (Fortune et al., 2002; Renzi et al.,
2002). For example, depressive symptoms predict anti-TNF
non-adherence in patients with inflammatory bowel disease
(Calloway et al., 2017). Low levels of self-efficacy, an individu-
al’s belief in their own ability to succeed in accomplishing a
task, have also been linked to non-adherence, suggesting
increasing patient self-injection confidence and empowerment
may help increase adherence levels (Nafradi et al., 2017).
Specific factors related to the disease area (e.g. rheumatol-
ogy-specific factors) and treatment may also contribute to
low adherence (Vangeli et al., 2015). Fear and anxiety about
self-injection, in the form of needle phobia, is a recognized
barrier to patient adherence (Cox & Mohr, 2003), and previ-
ous bad experiences with self-injection have been found to
affect the patient’s future experience of self-injection (Schiff
et al., 2017). Positive therapeutic clinical relationships and
skilled HCPs can help to reduce fear, improve patient well-
being, individualize person-centered care and foster a feeling
of support. For example, the development of rituals sur-
rounding the preparation and act of self-injection can help
patients’ control of the process and reduce anxiety (Schiff
et al., 2017).
5. A portfolio of devices can address a range of
patient needs
As discussed above, low patient adherence is caused by a
range of factors which are strongly individually determined.
The necessity-concern framework proposes that a patient’s
adherence decisions are a result of the balance between
their perceived need for medication (necessity) and their
concerns regarding its use (Horne et al., 1999; Phillips et al.,
2014). If an individual’s view of the necessity of their treat-
ment increases, while their concerns about its use decrease,
adherence to their treatment regimen will improve (Horne
et al., 2013). Effective device design provides one way to
reduce patient treatment concerns.
All self-injection devices can be developed to reduce
patient concerns about drug administration and help maxi-
mize the range of individuals it is suitable for. By involving
patients in the design of a device, for example through for-
mative HFS, device manufacturers can ensure they are devel-
oping devices that address patient needs (Domanska et al.,
2018). Syringe flanges or PFP grips can be designed ergo-
nomically to help increase the isometric force patients can
apply during an injection. As a result, this helps overcome
some of the challenges resulting from patient dexterity prob-
lems (Sheikhzadeh et al., 2012). Ergonomic syringe flanges
were preferred by patients, compared to a standard syringe
(Sheikhzadeh et al., 2012).
Having access to a portfolio of different injection devices
designed specifically for each treatment option allows physi-
cians, through discussions with patients, to adapt treatment
administration to different patients’ needs. The availability of
choice in self-injection devices is an important piece in the
‘eco-system’ of a comprehensive treatment landscape for
chronic disease management. Evidence suggests using a pre-
ferred device may increase patient tolerance of self-injection
and possibly improve adherence (Gau & Takasawa, 2017).
Generally, devices have been found to have a positive
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impact on the self-esteem of elderly patients if they feel they
are mastering the device (Thomson et al., 2013). However,
the same research found that a device could have a negative
impact on elderly patients’ self-esteem if they felt they had
no other choice but to use it (Thomson et al., 2013). This evi-
dence supports the use of a portfolio of devices, as a choice
between devices may help prevent patients from feeling
they have to use a specific device.
Injection-naïve patients often suffer increased self-
injection anxiety (Cox & Mohr, 2003; Karter et al., 2010).
The PFPs and e-Devices have been designed with hidden
needles, possibly reducing needle phobia (Domanska et al.,
2017b), and patient preference studies have found that
patients generally find PFPs easier to use than PFSs (Kivitz
et al., 2006). However, some patients have reported that a
PFS allows them more control over self-injection: a compari-
son study between a PFS and a PFP found patients who pre-
ferred the syringe often preferred it because the injection
was easier to control and less painful (Kivitz et al., 2006). RA
is associated with dexterity issues; easy to use self-injection
devices, such as PFPs, can improve ease of use and reduce
pain, potentially facilitating adherence to treatment (Kivitz &
Segurado, 2007). In particular, patient comments suggest the
larger grip of a PFP (‘it’s sturdy and the material on the han-
dle is anti-slip which made me feel more confident’) and aud-
ible indication clicks (‘two clicks [were] reassuring’) increase
patient confidence (Domanska et al., 2017b).
e-Devices have enhanced technological features that can
help with disease management (Collier et al., 2017;
Domanska et al., 2018). These features allow patients to com-
bine the ease of automated self-injection with increased self-
injection control. Previous studies have demonstrated that
medication reminders and treatment logs can improve treat-
ment adherence (Patel et al., 2013; Coorey et al., 2018); e-
Devices have the potential to incorporate these functions
allowing patients to check if it is time to administer an injec-
tion, potentially helping to prevent unconscious non-adher-
ence. As a result, this type of self-injection device may
appeal to busy patients or patients with cognitive problems
who may struggle to remember to carry out injections. The
injection log can also be used to foster discussions with
HCPs on reasons for non-adherence as injection history can
be accessed and missed injections and injection patterns
highlighted easily at clinic appointments (Domanska et al.,
2018). Previous studies have demonstrated that support from
HCPs can improve patient adherence (Mansoor et al., 2013),
and so an injection log that connects to a patient’s electronic
health records could identify patients at need of more direct
support. The ability to practice injections and the step-by-
step on-screen instructions can help patients increase their
confidence in their ability to self-inject correctly (Domanska
et al., 2018). Additionally, e-Devices permit personalization;
for example, the technology allows patients to choose
between different injection speeds (Domanska et al., 2018).
However, an e-Device may not be appropriate for patients
who are not at ease with technology.
In addition to a range of self-injection devices, patient
support services are available that aim to support
patients during self-injection. Support services provide edu-
cation on the injection process, disease and treatment, and
give patients an opportunity to share their experiences. This
encourages patients to ask about, and therefore resolve,
problems with successful self-injection. For example, a
patient support program (PSP) for adalimumab patients
includes patient education and injection training, delivery
and disposal of devices, financial assistance, patient
reminders and direct contact with specialist nurses (Bessette
et al., 2018). Several studies examining the impact of the
adalimumab PSP found adherence increased in those using
the service, compared to patients who were not (Hill et al.,
2001; Rubin et al., 2017; Bessette et al., 2018; Marshall et al.,
2018). Additionally, providing patients with information
about antirheumatic drugs in groups resulted in better out-
comes and increased adherence, compared to providing
information individually (Homer et al., 2009). A review of
studies reporting outcomes of PSPs found such services posi-
tively impact patient adherence, and patients enrolled in the
program have increased Patient Activation Measure (PAM)-13
scores (Ganguli et al., 2016; Van den Bosch et al., 2017). PAM
is a measure of how ‘activated’ a patient is and is a reliable
indicator of the level of patient knowledge and confidence
regarding their own health and care (Hibbard et al., 2004).
Although beneficial, additional PSPs can add complexity to
patients’ treatment journeys. The development of e-Devices
with functions such as connectivity and injection logging, can
provide many PSP benefits without further burdening
patients. In previous studies, patients described often feeling
over- burdened by self-injection, for example struggling to
remember how to inject (Schiff et al., 2017). Therefore, any ini-
tiatives that seamlessly combine injection devices with sup-
port services will likely lead to improved patient experience.
6. The future of drug-delivery devices
Injection is a common method of drug administration, and
injection devices are continually being developed. For
example, researchers are currently developing a needle-free
influenza vaccination – there may be the potential for adapt-
ing these innovations for use in biologic administration
(McAllister et al., 2014). Oral administration is generally pre-
ferred by patients and there is some evidence that it may
increase adherence (Quante et al., 2012). Oral administration
of large protein molecules represents unique challenges,
however, methods for biologic administration, particularly for
gastrointestinal disease indications such as Crohn’s disease,
are being developed. For example, oral administration of
anti-TNF to a mouse model of inflammatory bowel disease
was found to improve symptoms (Bhol et al., 2013).
Additionally, recent research into the development of an oral
biologic delivery system allowing injection of insulin into the
stomach lining demonstrated comparable plasma drug levels
to subcutaneous injection in animals (Abramson et al., 2019).
If proven effective in clinical trials, a similar delivery system
could be developed for the administration of other large
protein molecules, such as anti-TNFs.
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With the advent of e-Devices in rheumatology, ‘smart’
self-injection devices can not only make the act of self-inject-
ing easier but can also help patients manage their disease.
For example, a future self-injection e-Device, developed with
the ability to synchronize with a mobile phone application,
could help patients and HCPs track their treatment and
symptoms, provide education and increase patient confi-
dence and motivation to adhere to their treatment regimen.
This could be used to individualize treatment, help patients
self-manage their disease and increase independence. Phone
and computer applications available to support self-injection
and drug delivery in other disease areas, for example, mul-
tiple sclerosis and diabetes, have been found to increase
patient ability to track their own health and provide data for
improved patient-HCP communication (Mougiakakou et al.,
2010; Greiner et al., 2015).
In recent years, there has been an accelerated drive to
utilize artificial intelligence (AI) and machine learning algo-
rithms to support patient care (Jiang et al., 2017). Several
studies have investigated the potential uses of machine
learning in rheumatology. In one study, machine learning
was successfully used to predict disease flares by monitoring
levels of patient activity using activity trackers (Gossec et al.,
2018). In another study, machine learning was used to
develop a clinical prediction model for RA mortality
(Lezcano-Valverde et al., 2017). Similar innovations could be
developed by coupling machine learning to connected self-
injection devices; for example, it may be possible to monitor
changes in patient-reported outcome measures using
machine learning, this could then be used to predict disease
activity and make treatment recommendations.
7. Conclusions
Low adherence to treatment regimens is a well-documented
phenomenon in biologic drug research (Elliott, 2008; Bluett
et al., 2015; Lopez-Gonzalez et al., 2015). Reasons behind
non-adherence are complex but evidence suggests they
often originate from a lack of patient confidence or engage-
ment (Nafradi et al., 2017; Maniadakis et al., 2018).
Supporting patients through PSPs and devices that address
patient needs can increase confidence and motivation, and
improve adherence (Nafradi et al., 2017; Rubin et al., 2017).
To ensure that self-injection devices are best designed to
help overcome treatment administration challenges, device
design and development should be centered around the
patient. Published results from HFS and preference studies
demonstrates the heterogeneity that exists in patient prior-
ities and highlights how a single self-injection device cannot
support the needs of all patient groups (Fraenkel et al., 2004;
Kivitz et al., 2006; Domanska et al., 2017a; Domanska et al.,
2018; Maniadakis et al., 2018). By providing a choice of self-
injection devices HCPs will be able to support a larger pro-
portion of patients and empower them to take control of
their personal treatment journey. As discussed above, this
has the potential to improve patient experience and treat-
ment adherence, improve clinical outcomes, and reduce the
economic and societal burden of disease.
Acknowledgments
The authors acknowledge Susanne Wiegratz, UCB Pharma, Monheim,
Germany for publication coordination and Emma Phillips, PhD, and
Simon Foulcer, PhD, from Costello Medical, UK, for medical writing and
editorial assistance in preparing this manuscript for publication, based
on the authors’ input and direction.
Disclosure statement
BVB: Received grant/research support from: UCB, Pfizer, AbbVie;
Speakers bureau: Pfizer, AbbVie, UCB, Biogen, Sandoz. Delivered consult-
ancy work for UCB, Novartis and Pfizer.LG: Delivered consultancy work
for UCB, Sanofi and Jackel Solutions.BD: Employee of UCB Pharma.RB:
Employee of UCB Pharma.IM: Employee of UCB Pharma.LEK: Received
grant/research support from: UCB, Biogen, Janssen Pharmaceuticals, and
Novartis; Speakers bureau: Pfizer, AbbVie, Amgen, UCB, BMS, Biogen,
MSD, Novartis, Eli Lilly and Company, and Janssen Pharmaceuticals.
Funding
UCB funded the review and the development of the manuscript and
reviewed the text to ensure that from the perspective of UCB, the data
presented in the publication are scientifically, technically and medically
supportable, that they do not contain any information that has the
potential to damage the intellectual property of UCB, and that the publi-
cation complies with applicable laws, regulations, guidelines and good
industry practice. The authors approved the final version to be published
after critically revising the manuscript/publication for important intellec-
tual content.
References
Abramson A, Caffarel-Salvador E, Khang M, et al. (2019). An ingestible
self-orienting system for oral delivery of macromolecules. Science 363:
611–5.
Bessette L, Lebovic G, Millson B, et al. (2018). Impact of the adalimumab
patient support program on clinical outcomes in ankylosing spondyl-
itis: results from the COMPANION study. Rheumatol Ther 5:75–85.
Bhol KC, Tracey DE, Lemos BR, et al. (2013). AVX-470: a novel oral anti-
TNF antibody with therapeutic potential in inflammatory bowel dis-
ease. Inflamm Bowel Dis 19:2273–81.
Bluett J, Morgan C, Thurston L, et al. (2015). Impact of inadequate adher-
ence on response to subcutaneously administered anti-tumour necro-
sis factor drugs: results from the Biologics in Rheumatoid Arthritis
Genetics and Genomics Study Syndicate cohort. Rheumatology
(Oxford) 54:494–9.
Borras-Blasco J, Gracia-Perez A, Castera MD, et al. (2013). Educational ses-
sion as a tool to increase patient satisfaction of switching etanercept
from the prefilled syringe to the autoinjection pen. Expert Opin Biol
Ther 13:1103–8.
Bugni VM, Ozaki LS, Okamoto KY, et al. (2012). Factors associated with
adherence to treatment in children and adolescents with chronic
rheumatic diseases. J Pediatr (Rio J) 88:483–8.
Calloway A, Dalal R, Beaulieu DB, et al. (2017). Depressive symptoms pre-
dict anti-tumor necrosis factor therapy noncompliance in patients
with inflammatory bowel disease. Dig Dis Sci 62:3563–7.
Collier DH, Bitman B, Coles A, et al. (2017). A novel electromechanical
autoinjector, AutoTouch, for self-injection of etanercept: real-world
use and benefits. Postgrad Med 129:118–25.
Coorey GM, Neubeck L, Mulley J, et al. (2018). Effectiveness, acceptability
and usefulness of mobile applications for cardiovascular disease self-
management: Systematic review with meta-synthesis of quantitative
and qualitative data. Eur J Prev Cardiol 25:505–21.
Cox D, Mohr DC. (2003). Managing difficulties with adherence to inject-
able medications due to blood, injection, and injury phobia and self-
injection anxiety. American Journal of Drug Delivery 1:215–21.
390 B. J. F. VAN DEN BEMT ET AL.
Cross MJ, March LM, Lapsley HM, et al. (2006). Patient self-efficacy and
health locus of control: relationships with health status and arthritis-
related expenditure. Rheumatology (Oxford) 45:92–6.
Domanska B, Mountian I, Vinconneau G. (2017a). Patient-preferred
design features of TNF inhibitor self-injection devices: insights from a
rheumatoid arthritis auto-injector preference study. Value in Health
20:A591–2.
Domanska B, Stumpp O, Poon S, et al. (2018). Using patient feedback to
optimize the design of a certolizumab pegol electromechanical self-
injection device: insights from human factors studies. Adv Ther 35:
100–15.
Domanska B, VanLunen B, Peterson L, et al. (2017b). Comparative usabil-
ity study for a certolizumab pegol autoinjection device in patients
with rheumatoid arthritis. Expert Opin Drug Deliv 14:15–22.
Elliott RA. (2008). Poor adherence to medication in adults with rheuma-
toid arthritis. Disease Management & Health Outcomes 16:13–29.
EMA, (2018). Summary of product characteristics: benepali. https://www.
ema.europa.eu/documents/product-information/benepali-epar-prod-
uct-information_en.pdf
FDA, (2016a). Applying human factors and usability engineering to med-
ical devices: guidance for industry and Food and Drug Administration
staff. https://www.fda.gov/downloads/MedicalDevices/… /UCM259760.
pdf.
FDA, (2016b). Human factors studies and related clinical study considera-
tions in combination product design and development: draft guid-
ance for industry and FDA staff. https://www.fda.gov/downloads/
RegulatoryInformation/Guidances/UCM484345.pdf.
Feldman SR. (2013). Disease burden and treatment adherence in psoria-
sis patients. Cutis 92:258–63.
Fidder HH, Singendonk MM, van der Have M, et al. (2013). Low rates of
adherence for tumor necrosis factor-alpha inhibitors in Crohn’s dis-
ease and rheumatoid arthritis: results of a systematic review. World J
Gastroenterol 19:4344–50.
Finckh A, Escher M, Liang MH, et al. (2016). Preventive Treatments for
Rheumatoid Arthritis: Issues Regarding Patient Preferences. Curr
Rheumatol Rep 18:51.
Fortune DG, Richards HL, Kirby B, et al. (2002). A cognitive-behavioural
symptom management programme as an adjunct in psoriasis therapy.
Br J Dermatol 146:458–65.
Fraenkel L, Bogardus ST, Concato J, et al. (2004). Patient preferences for
treatment of rheumatoid arthritis. Ann Rheum Dis 63:1372–8.
French-Mowat E, Burnett J. (2012). How are medical devices regulated in
the European Union? Journal of the Royal Society of Medicine 105:
S22–S28.
Freundlich B, Kivitz A, Jaffe JS. (2014). Nearly pain-free self-administration
of subcutaneous methotrexate with an autoinjector: results of a phase
2 clinical trial in patients with rheumatoid arthritis who have func-
tional limitations. J Clin Rheumatol 20:256–60.
Gadallah MA, Boulos DN, Gebrel A, et al. (2015). Assessment of rheuma-
toid arthritis patients’ adherence to treatment. Am J Med Sci 349:
151–6.
Galo JS, Mehat P, Rai SK, et al. (2016). What are the effects of medication
adherence interventions in rheumatic diseases: a systematic review.
Ann Rheum Dis 75:667–73.
Ganguli A, Clewell J, Shillington AC. (2016). The impact of patient sup-
port programs on adherence, clinical, humanistic, and economic
patient outcomes: a targeted systematic review. Patient Prefer
Adherence 10:711–25.
Gau M, Takasawa K. (2017). Initial patient choice of a growth hormone
device improves child and adolescent adherence to and therapeutic
effects of growth hormone replacement therapy. J Pediatr Endocrinol
Metab 30:989–93.
Gossec L, Guyard F, Leroy D, et al. (2018). Detection of flares by decrease
in physical activity, collected using wearable activity trackers, in
rheumatoid arthritis or axial spondyloarthritis: an application of
Machine-Learning analyses in rheumatology. Arthritis Care Res
(Hoboken). doi:10.1002/acr.23768.
Greiner P, Sawka A, Imison E. (2015). Patient and physician perspectives
on MSdialog, an electronic PRO diary in multiple sclerosis. Patient 8:
541–50.
Harrison M, Marra C, Shojania K, et al. (2015). Societal preferences for
rheumatoid arthritis treatments: evidence from a discrete choice
experiment. Rheumatology (Oxford) 54:1816–25.
Hibbard JH, Stockard J, Mahoney ER, et al. (2004). Development of the
Patient Activation Measure (PAM): conceptualizing and measuring
activation in patients and consumers. Health Serv Res 39:1005–26.
Hider SL, Tanveer W, Brownfield A, et al. (2009). Depression in RA
patients treated with anti-TNF is common and under-recognized in
the rheumatology clinic. Rheumatology (Oxford) 48:1152–4.
Hill J, Bird H, Johnson S. (2001). Effect of patient education on adherence
to drug treatment for rheumatoid arthritis: a randomised controlled
trial. Ann Rheum Dis 60:869–75.
Homer D, Nightingale P, Jobanputra P. (2009). Providing patients with
information about disease-modifying anti-rheumatic drugs: individu-
ally or in groups? A pilot randomized controlled trial comparing
adherence and satisfaction. Musculoskeletal Care 7:78–92.
Horne R, Chapman SC, Parham R, et al. (2013). Understanding patients’
adherence-related beliefs about medicines prescribed for long-term
conditions: a meta-analytic review of the Necessity-Concerns
Framework. PLoS One 8:e80633.
Horne R, Weinman J, Hankins M. (1999). The beliefs about medicines
questionnaire: the development and evaluation of a new method for
assessing the cognitive representation of medication. Psychology &
Health 14:1–24.
Jiang F, Jiang Y, Zhi H, et al. (2017). Artificial intelligence in healthcare:
past, present and future. Stroke Vasc Neurol 2:230–43.
Joplin S, van der Zwan R, Joshua F, et al. (2015). Medication
adherence in patients with rheumatoid arthritis: the effect of patient
education, health literacy, and musculoskeletal ultrasound. Biomed
Res Int 2015:150658.
Jørgensen TS, Skougaard M, Taylor PC, et al. (2018). The Parker Model:
applying a qualitative three-step approach to optimally utilize input
from stakeholders when introducing new device technologies in the
management of chronic rheumatic diseases. Patient 11:515–26.
Karter AJ, Subramanian U, Saha C, et al. (2010). Barriers to insulin initi-
ation: the translating research into action for diabetes insulin starts
project. Diabetes Care 33:733–5.
Keininger D, Coteur G. (2011). Assessment of self-injection experience in
patients with rheumatoid arthritis: psychometric validation of the
Self-Injection Assessment Questionnaire (SIAQ). Health Qual Life
Outcomes 9:2.
Kivitz A, Cohen S, Dowd JE, et al. (2006). Clinical assessment of pain, tol-
erability, and preference of an autoinjection pen versus a prefilled syr-
inge for patient self-administration of the fully human, monoclonal
antibody adalimumab: the TOUCH trial. Clin Ther 28:1619–29.
Kivitz A, Segurado OG. (2007). HUMIRA pen: a novel autoinjection device
for subcutaneous injection of the fully human monoclonal antibody
adalimumab. Expert Rev Med Devices 4:109–16.
Lange J, Richard P, Bradley N. (2014). Usability of devices for self-injec-
tion: results of a formative study on a new disposable pen injector.
Med Devices (Auckl) 7:195–203.
Lange J, Richard P, Bradley N. (2015). Usability of a new disposable auto-
injector platform device: results of a formative study conducted with
a broad user population. Med Devices (Auckl) 8:255–64.
Lezcano-Valverde JM, Salazar F, Leon L, et al. (2017). Development and
validation of a multivariate predictive model for rheumatoid arthritis
mortality using a machine learning approach. Scientific Reports 7:
10189.
Lopez-Gonzalez R, Leon L, Loza E, et al. (2015). Adherence to biologic
therapies and associated factors in rheumatoid arthritis, spondyloar-
thritis and psoriatic arthritis: a systematic literature review. Clin Exp
Rheumatol 33:559–69.
Lyseng-Williamson KA. (2017). Certolizumab pegol administration devi-
ces: a profile of their use and usability. Drugs Ther Perspect 33:
515–22.
Makwana S, Basu B, Makasana Y, et al. (2011). Prefilled syringes: an
innovation in parenteral packaging. Int J Pharm Investig 1:200–6.
Mangham LJ, Hanson K, McPake B. (2009). How to do (or not to do) …
Designing a discrete choice experiment for application in a low-
income country. Health Policy and Planning 24:151–8.
DRUG DELIVERY 391
Maniadakis N, Toth E, Schiff M, et al. (2018). A targeted literature review
examining biologic therapy compliance and persistence in chronic
inflammatory diseases to identify the associated unmet needs, driving
factors, and consequences. Adv Ther 35:1333–55.
Mansoor SM, Krass I, Aslani P. (2013). Multiprofessional interventions to
improve patient adherence to cardiovascular medications. J
Cardiovasc Pharmacol Ther 18:19–30.
Marshall JK, Bessette L, Thorne C, et al. (2018). Impact of the adalimu-
mab patient support program’s care coach calls on persistence and
adherence in Canada: an observational retrospective cohort study.
Clinical Therapeutics 40:415–29.e6.
Maruotti N, Cantatore FP. (2014). Impact of biological therapy on spon-
dyloarthritis. Eur J Clin Pharmacol 70:1021–7.
Matcham F, Norton S, Scott DL, et al. (2016). Symptoms of depression
and anxiety predict treatment response and long-term physical health
outcomes in rheumatoid arthritis: secondary analysis of a randomized
controlled trial. Rheumatology (Oxford) 55:268–78.
McAllister L, Anderson J, Werth K, et al. (2014). Needle-free jet injection
for administration of influenza vaccine: a randomised non-inferiority
trial. Lancet 384:674–81.
Mease PJ. (2015). Biologic therapy for psoriatic arthritis. Rheum Dis Clin
North Am 41:723–38.
MHRA, (2017). Human factors and usability engineering – guidance for
medical devices including drug-device combination products.
London, UK: MHRA.
Michetti P, Weinman J, Mrowietz U, et al. (2017). Impact of Treatment-
Related Beliefs on Medication Adherence in Immune-Mediated
Inflammatory Diseases: Results of the Global ALIGN Study. Adv Ther
34:91–108.
Morgan C, McBeth J, Cordingley L, et al. (2015). The influence of behav-
ioural and psychological factors on medication adherence over time
in rheumatoid arthritis patients: a study in the biologics era.
Rheumatology (Oxford) 54:1780–91.
Mougiakakou SG, Bartsocas CS, Bozas E, et al. (2010). SMARTDIAB: a com-
munication and information technology approach for the intelligent
monitoring, management and follow-up of type 1 diabetes patients.
IEEE Trans Inform Technol Biomed 14:622–33.
Muller-Ladner U, Flipo RM, Vincendon P, et al. (2012). Comparison of
patient satisfaction with two different etanercept delivery systems. A
randomised controlled study in patients with rheumatoid arthritis. Z
Rheumatol 71:890–9.
Nafradi L, Nakamoto K, Schulz PJ. (2017). Is patient empowerment the
key to promote adherence? A systematic review of the relationship
between self-efficacy, health locus of control and medication adher-
ence. PLoS One 12:e0186458.
Panescu D. (2009). Medical device development. Conf Proc IEEE Eng Med
Biol Soc 2009:5591–4.
Pasma A, Schenk CV, Timman R, et al. (2015). Non-adherence to disease-
modifying antirheumatic drugs is associated with higher disease activ-
ity in early arthritis patients in the first year of the disease. Arthritis
Res Ther 17:281.
Pasma A, van’t Spijker A, Hazes JM, et al. (2013). Factors associated with
adherence to pharmaceutical treatment for rheumatoid arthritis
patients: a systematic review. Semin Arthritis Rheum 43:18–28.
Patel S, Jacobus-Kantor L, Marshall L, et al. (2013). Mobilizing your medi-
cations: an automated medication reminder application for mobile
phones and hypertension medication adherence in a high-risk urban
population. J Diabetes Sci Technol 7:630–9.
Phillips LA, Diefenbach MA, Kronish IM, et al. (2014). The necessity-con-
cerns framework: a multidimensional theory benefits from multidi-
mensional analysis. Ann Behav Med 48:7–16.
Quante M, Thate-Waschke I, Schofer M. (2012). What are the reasons for
patient preference? A comparison between oral and subcutaneous
administration. Z Orthop Unfall 150:397–403.
Renzi C, Picardi A, Abeni D, et al. (2002). Association of dissatisfaction
with care and psychiatric morbidity with poor treatment compliance.
Arch Dermatol 138:337–42.
Rubin DT, Mittal M, Davis M, et al. (2017). Impact of a patient support
program on patient adherence to adalimumab and direct medical
costs in Crohn’s disease, ulcerative colitis, rheumatoid athritis, psoria-
sis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec
Pharm 23:859–67.
Saini SD, Schoenfeld P, Kaulback K, et al. (2009). Effect of medication
dosing frequency on adherence in chronic diseases. Am J Manag Care
15:e22–33.
Salmon P, Hall GM. (2003). Patient empowerment and control: a psycho-
logical discourse in the service of medicine. Soc Sci Med 57:1969–80.
Schiff M, Koo J, Jin E, et al. (2016). Usability and acceptability of the aba-
tacept pre-filled autoinjector for the subcutaneous treatment of
rheumatoid arthritis. Adv Ther 33:199–213.
Schiff M, Saunderson S, Mountian I, et al. (2017). Chronic disease and
self-injection: ethnographic investigations into the patient experience
during treatment. Rheumatol Ther 4:445–63.
Schulze-Koops H, Giacomelli R, Samborski W, et al. (2015). Factors influ-
encing the patient evaluation of injection experience with the
SmartJect autoinjector in rheumatoid arthritis. Clin Exp Rheumatol 33:
201–8.
Schwartzman S, Morgan GJ. Jr. (2004). Does route of administration
affect the outcome of TNF antagonist therapy? Arthritis Res Ther 6:
S19–S23.
Sheikhzadeh A, Yoon J, Formosa D, et al. (2012). The effect of a new syr-
inge design on the ability of rheumatoid arthritis patients to inject a
biological medication. Appl Ergon 43:368–75.
Sivamani RK, Goodarzi H, Garcia MS, et al. (2013). Biologic therapies in
the treatment of psoriasis: a comprehensive evidence-based basic sci-
ence and clinical review and a practical guide to tuberculosis moni-
toring. Clinic Rev Allergy Immunol 44:121–40.
Thomson R, Martin JL, Sharples S. (2013). The psychosocial impact of
home use medical devices on the lives of older people: a qualitative
study. BMC Health Serv Res 13:467.
Trivedi I, Hanauer SB. (2015). Balancing the risks and benefits of biologic
therapy in inflammatory bowel diseases. Expert Opin Drug Saf 14:
1915–34.
van den Bemt BJ, van Lankveld WG. (2007). How can we improve adher-
ence to therapy by patients with rheumatoid arthritis? Nat Clin Pract
Rheumatol 3:681.
Van den Bosch F, Wassenberg S, €Ost€or A, et al. (2017). Impact of patient
support program utilization on patient activation measure scores
among patients with rheumatoid arthritis [abstract]. Arthritis
Rheumatol 69. https://acrabstracts.org/abstract/impact-of-patient-sup-
port-program-utilization-on-patient-activation-measure-scores-among-
patients-with-rheumatoid-arthritis/
Vangeli E, Bakhshi S, Baker A, et al. (2015). A systematic review of factors
associated with non-adherence to treatment for immune-mediated
inflammatory diseases. Adv Ther 32:983–1028.
Vermeire S, D’Heygere F, Nakad A, et al. (2018). Preference for a prefilled
syringe or an auto-injection device for delivering golimumab in
patients with moderate-to-severe ulcerative colitis: a randomized
crossover study. Patient Prefer Adherence 12:1193–202.
Wang D, Li Y, Liu Y, et al. (2014). The use of biologic therapies in the
treatment of rheumatoid arthritis. Curr Pharm Biotechnol 15:542–8.
392 B. J. F. VAN DEN BEMT ET AL.
